Dicerna Pharmaceuticals has named one of its co-founders, Douglas Fambrough, as its new CEO.
Fambrough will replace Jim Jensen, another Dicerna co-founder, who will remain on the company's board of directors and scientific advisory board.
Fambrough most recently served as general partner at Oxford Bioscience Partners, where he led the venture capital firm's investment in Sirna Therapeutics. Before joining Oxford, he was a researcher at the Whitehead/MIT Center for Genomic Research, now known as the Broad Institute.
Silence Therapeutics said it has promoted Jorg Kaufmann, its senior director of technologies, to the position of vice president of research.
Kaufmann holds a PhD in molecular biology from Philipps University Marburg.